» Factor VIII Inhibitor Plasma HCV neg

ROUTINE INHIBITOR NIJMEGEN BETHESDA ASSAYS FVIII INHIBITOR NIJMEGEN BETHESDA CONTROLS

Factor VIII Inhibitor Plasma HCV neg

Lyophilized plasmas

Human plasma depleted in Factor VIII containing an added anti-FVIII inhibitor.
This plasma can be used for the negative control of the determination of Factor VIII (FVIII) inhibitor according to the Bethesda assays or modified Nijmegen Bethesda assays.

The FVIII Inhibitor Control Plasma, HCV negative, is a normal human plasma immuno-absorbed with an added specific inhibitory antibody, directed against the activity of factor VIII (FVIII: C).

Reference	Presentation	Packaging
4-5159010	Vial	5 x 1.0 mL

Price list, safety data sheets and notices are accessible to our registered customers.

Treatment for hemophilia A consists of injecting the missing Factor VIII by I.V. to prevent or stop the bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.

The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by the Bethesda assay or modified Nijmegen Bethesda and is expressed in BU. 1BU neutralizes 50% of the activity of FVIII for hemophilia A.

Plasma with HCV negative FVIII inhibitor can be used :

- As a control for determining the Bethesda Units (BU) title
- Title in Bethesda Unit depending on lots and tests
- For the accuracy control of the FVIII inhibitor determination based on the Bethesda test
- 1 month stability after reconstitution

- 5 vials x 1 mL lyophilized plasma

CRYOcheck™ Factor VIII Inhibitor Kit
Factor IX Inhibitor Plasma Negative Control
Factor IX Inhibitor Plasma Weak Control
Factor VIII Inhibitor Plasma
Factor VIII Inhibitor Plasma Negative Control
Factor VIII Inhibitor Plasma Weak Control

	These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
	These kits are intended for in vitro diagnostic use.
	These kits are for research use only and are not intended to be used for diagnostic procedures.
	Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
	Biological risk products.
	Storage between 2 and 8 ° C.
	Reactive in liquid form.
	Reactive in lyophilized form.
	Reactive in frozen form.
	Stability after opening at 2-8 ° C.
	Products that can be refrozen.
	Stability 12 months after refreezing at -20 ° C.
	Manufacturer.
	Importer.
	Distributor.

ROUTINE INHIBITOR NIJMEGEN BETHESDA ASSAYS FVIII INHIBITOR NIJMEGEN BETHESDA CONTROLS

Factor VIII Inhibitor Plasma HCV neg

Lyophilized plasmas

Price list, safety data sheets and notices are accessible to our registered customers.

Cryopep Catalogue
Thrombosis Haemostasis 2023

Cryopep Catalogue
Haemostasis Research 2023

Cryopep INHIBITOR NIJMEGEN BETHESDA ASSAYS

Product sheet Factor VIII Inhibitor Plasma HCV neg

Miller CH. et al. Haemophilia. 2018

Duncan E. et al. Methods in Molecular Biology 2013

You must identify yourself to search for a certificate of analysis

Factor VIII Inhibitor Plasma HCV neg

Lyophilized plasmas

Product sheet

Price list, safety data sheets and notices are accessible to our registered customers.